Reduction in physician reimbursement and use of hormone therapy in prostate cancer

Journal of the National Cancer Institute

Volumn 102, Issue 24, 2010, Pages 1826-1834

  Elliott, Sean P ^a,b,c   Jarosek, Stephanie L ^b   Wilt, Timothy J ^d,e   Virnig, Beth A ^b,c  

^a University School of Medicine   (United States)

^b Public Health   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BRACHYTHERAPY; CANCER GRADING; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER REGISTRY; CANCER RISK; CANCER STAGING; COHORT ANALYSIS; COMORBIDITY; CRYOABLATION; EDUCATIONAL STATUS; HUMAN; HYPERTHERMIC THERAPY; INCOME; MAJOR CLINICAL STUDY; MALE; MEDICARE; METASTASIS; PREDICTION; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATECTOMY; RACE DIFFERENCE; REIMBURSEMENT; WORLD HEALTH ORGANIZATION;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; DRUG PRESCRIPTIONS; HEALTH RESOURCES; HUMANS; LOGISTIC MODELS; MALE; MEDICARE; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; NEOPLASMS, HORMONE-DEPENDENT; ODDS RATIO; PALLIATIVE CARE; PROSTATIC NEOPLASMS; RADIOTHERAPY, ADJUVANT; SEER PROGRAM; UNITED STATES;

EID: 78650354540     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djq417     Document Type: Article

References (34)

1. Horsely, S. "Obama: Overtreatment drives health care costs." All Things Considered on National Public Radio; July 21, 2009. http://www.npr.org/ templates/story/story.php?storyId=106859968.
2. Brownlee S. Overtreated: Why Too Much Medicine is Making us Sicker and Poorer. 1st U.S. ed. New York, NY: Bloomsbury: Distributed to the trade by Holtzbrinck Publishers; 2007.
3. Gawande A. The cost conundrum. The New Yorker 2009. June 1, 2009;.
4. Arrow K. Uncertainty and the welfare economics of medical care. Am Econ Rec. 1963;53:941-973.
5. Wennberg JE, Cooper MM. Dartmouth Atlas of Health Care.Chicago, IL: American Hospital Publishing; 1996.
6. Walsh PC, DeWeese TL, Eisenberger MA. A structured debate: immediate versus deferred androgen suppression in prostate cancer-evidence for deferred treatment. J Urol. 2001;166(2):508-515.
7. Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet. 2002;360(9327):103-106.
8. Keating NL, O'Malley AJ, McNaughton-Collins M, Oh WK, Smith MR. Use of androgen deprivation therapy for metastatic prostate cancer in older men. BJU Int. 2008;101(9):1077-1083.
9. Braga-Basaria M, Dobs AS, Muller DC, et al. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol. 2006;24(24):3979-3983. (Pubitemid 46630747)
10. Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006;24(27):4448-4456.
11. Oefelein MG. Health related quality of life using serum testosterone as the trigger to re-dose long acting depot luteinizing hormone-releasing hormone agonists in patients with prostate cancer. J Urol. 2003;169(1): 251-255.
12. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med. 2005;352(2): 154-164.
13. Smith MR, Finkelstein JS, McGovern FJ, et al. Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab. 2002;87(2):599-603.
14. Practice Guidelines Committee of the American Urological Association. Guideline for the management of clinically localized prostate cancer: 2007 update. Americal Urological Association. 27-28. http://www.auanet.org /content/guidelines-and-quality-care/clinical-guidelines/main-reports /proscan07/content.pdf.
15. NCCN. National Comprehensive Cancer Network Practice Guidelines in Oncology: Prostate Cancer. Fort Washington, PA: National Comprehensive Cancer Network. Version 2.2009; 2004.
16. Shahinian VB, Kuo YF, Freeman JL, Orihuela E, Goodwin JS. Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma. Cancer. 2005;103(8):1615-1624.
17. McKoy JM, Lyons EA, Obadina E, et al. Caveat medicus: consequences of federal investigations of marketing activities of pharmaceutical suppliers of prostate cancer drugs. J Clin Oncol. 2005;23(34):8894-8905.
18. Weight CJ, Klein EA, Jones JS. Androgen deprivation falls as orchiectomy rates rise after changes in reimbursement in the U.S. Medicare population. Cancer. 2008;112(10):2195-2201.
19. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-383.
20. Klabunde CN, Potosky AL, Legler JM, Warren JL. Development of a comorbidity index using physician claims data. J Clin Epidemiol. 2000; 53(12):1258-1267.
21. Hu JC, Hevelone ND, Ferreira MD, et al. Patterns of care for radical prostatectomy in the United States from 2003 to 2005. J Urol. 2008;180(5): 1969-1974.
22. Conti PD, Atallah AN, Arruda H, Soares BG, El Dib RP, Wilt TJ. Intermittent versus continuous androgen suppression for prostatic cancer. Cochrane Database Syst Rev. 2007;(4):CD005009.
23. Siddiqui AK, Ahmed S, Delbeau H, Conner D, Mattana J. Lack of physician concordance with guidelines on the perioperative use of beta-blockers. Arch Intern Med. 2004;164(6):664-667.
24. Soloway MS, Pareek K, Sharif R, et al. Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results. J Urol. 2002;167(1):112-116.
25. Soloway MS, Sharif R, Wajsman Z, McLeod D, Wood Jr. DP, Puras-Baez A. Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer. The Lupron Depot Neoadjuvant Prostate Cancer Study Group. J Urol. 1995;154(2 pt 1):424-428.
26. Bolla M, Gonzalez D, Warde P, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med. 1997;337(5):295-300.
27. Pilepich MV, Caplan R, Byhardt RW, et al. Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with defnitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31. J Clin Oncol. 1997;15(3): 1013-1021.
28. Warren JL, Harlan LC, Fahey A, et al. Utility of the SEER-Medicare data to identify chemotherapy use. Med Care. 2002;40(8 suppl):IV-55-61.
29. Cooper GS, Virnig B, Klabunde CN, Schussler N, Freeman J, Warren JL. Use of SEER-Medicare data for measuring cancer surgery. Med Care. 2002;40(8 suppl):IV-43-48.
30. Virnig BA, Warren JL, Cooper GS, Klabunde CN, Schussler N, Freeman J. Studying radiation therapy using SEER-Medicare-linked data. Med Care. 2002;40(8 suppl):IV-49-54.
31. Kondylis FI, Moriarty RP, Bostwick D, Schellhammer PF. Prostate cancer grade assignment: the effect of chronological, interpretive and translation bias. J Urol. 2003;170(4 pt 1):1189-1193.
32. Painter MR. Reimbursement issues with hormonal therapies for prostate cancer. Rev Urol. 2005;7(suppl 5): S44-S47.
33. Jacobson M, O'Malley AJ, Earle CC, Pakes J, Gaccione P, Newhouse JP. Does reimbursement infuence chemotherapy treatment for cancer patients? Health Aff (Millwood). 2006;25(2):437-443.
34. Services DoHaH. Medicare Reimbursement for Lupron. Washington, DC: Offce of the Inspector General, Department of Health and Human Services. http://oig.hhs.gov/oei/reports/oei-03-03-00250.pdf Pub. No. OEI-03-03-00250.